Poly (ADP‐ribose) polymerase (PARP) inhibitors of BRCA1/2 and ATM, such as Olaparib, have been approved by US FDA for breast cancer and ovarian cancer treatment. This evidence concerns the gene BRCA1 and ovarian cancer.